Basal Bolus — Competitive Intelligence Brief

Basal Bolus (Basal Bolus) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin regimen. Area: Diabetes.

marketed Insulin regimen Insulin receptor Diabetes Small molecule

Target snapshot

Basal Bolus (Basal Bolus) — University of Campania Luigi Vanvitelli. Basal Bolus is an insulin regimen that mimics physiological insulin secretion by combining long-acting basal insulin with rapid-acting bolus insulin at meals.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Basal Bolus TARGET	Basal Bolus	University of Campania Luigi Vanvitelli	marketed	Insulin regimen	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin regimen class)

1. University of Campania Luigi Vanvitelli · 1 drug in this class